Ibrutinib plus venetoclax for previously treated CLL: CLARITY trial
Ibrutinib plus venetoclax for previously treated CLL: CLARITY trial
Data from the JULIET trial of CTL019 for relapsed or refractory diffuse large B-cell lymphoma
ECHELON-1 study of brentuximab vedotin as frontline therapy for Hodgkin's lymphoma
Long term follow up on the ZUMA-1 trial for nHL
BLU-285 for advanced systemic mastocytosis
SABCS 2017: The latest in CDK inhibition in breast cancer
Autologous haematopoietic cell transplant for mantle cell lymphoma
Dexamethasone and the UKALL 2011 trial
Circulating tumour cells may predict late recurrence in HR-positive breast cancer patients
Postmenopausal women who lose weight may have reduced breast cancer risk
Talazoparib vs physicians choice for patients with mBRCA1 breast cancer
CDK 4/6 inhibitors for older women with HR-positive breast cancer